Home > Nephrology > ERA 2025 > Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Nefecon maintains kidney function regardless of baseline status over 24 months in IgA nephropathy

Presented by
Prof. Jonathan Barratt, University of Leicester, UK
Conference
ERA 2025
Trial
Phase 3, NefIgArd
In the phase 3 NefIgArd trial, nefecon versus placebo showed improvement in eGFR and proteinuria in patients with IgA nephropathy, over 9 months of therapy and the subsequent 15 months of follow-up, regardless of baseline eGFR status.

Prof. Jonathan Barratt (University of Leicester, UK) described a subanalysis of NefIgArd, a phase 3 trial assessing nefecon 16 mg/day versus placebo in adults with IgA nephropathy [1]. Trial participants had an eGFR between 35–90 mL/min/1.73 m2 and a urinary protein-creatinine ratio (uPCR) ≥0.1 g/day despite optimised RAS inhibitor treatment [2]. This subanalysis focused on the effect of therapy on eGFR decline over the 9 months of therapy and through 15 months of follow-up, and included 182 participants in each treatment group [1].

Among subgroups defined by eGFR deciles ( ≤38/>38, ≤43/>43, ≤47/>47, ≤51/>51, ≤55/>55, ≤60/>60, ≤66/>66, ≤72/>72, and ≤82/>82 mL/min/1.73 m2), nefecon versus placebo consistently showed improvement in eGFR after 9 months of treatment, but also at 12 months and 24 months of the trial during the follow-up period. Similarly, nefecon versus placebo led to an improvement in uPCR across all eGFR deciles and at the same assessed timepoints.

“This subanalysis of the NefIgArd study demonstrates that the efficacy of 9 months of nefecon treatment in the preservation of kidney function and reduction in proteinuria was independent of baseline eGFR,” concluded Prof. Barrat. “This effect was seen both after 9 months of treatment and throughout the remaining 15-month off-treatment period. I think we are going to see a lot more of these analyses as we have more and more treatments available because, as clinicians, we are seeing patients, and we need to best understand how particular patient phenotypes allow us to use one drug over another.”

  1. Barratt J, et al. Nefecon provides kidney benefit irrespective of baseline eGFR in patients with IgAN: A subanalysis of the NefIgArd study. 62nd ERA Congress, 4–7 June 2025, Vienna, Austria.
  2. Lafayette J, et al. Lancet. 2023;402(10405):859-870.

Medical writing support was provided by Mihai Surducan, PhD.

Copyright ©2025 Medicom Medical Publishers



Posted on